CONBA(SH:600572)2020-10-27 16:00Financial Performance - The company achieved operating revenue of RMB 4.542 billion in Q3 2020, a decrease of 15.77% compared to the same period last year[11]. - Net profit attributable to shareholders reached RMB 543.82 million, an increase of 14.63% year-on-year[11]. - Total revenue for Q3 2020 was CNY 1,347,443,458.48, a decrease of 22.7% compared to CNY 1,743,203,165.20 in Q3 2019[48]. - Net profit for Q3 2020 was CNY 88,544,936.55, compared to CNY 104,473,259.06 in Q3 2019, indicating a decline of 15.2%[51]. - The company's net profit attributable to shareholders for Q3 2020 was ¥60,369,243.27, a decrease from ¥84,625,994.14 in Q3 2019, representing a decline of approximately 28.7%[54]. - The total comprehensive income attributable to the parent company for Q3 2020 was ¥60,229,479.69, down from ¥84,810,039.18 in Q3 2019, a decline of about 29.1%[56]. - The net profit for the first three quarters of 2020 was ¥303,895,466.77, compared to ¥305,745,430.58 in the same period of 2019, showing a slight decrease of about 0.6%[60]. - The total revenue for the first three quarters of 2020 was ¥410,768,391.79, down from ¥452,018,576.43 in the same period of 2019, reflecting a decrease of approximately 9.1%[56]. Revenue Breakdown - Self-care product revenue grew to RMB 2.372 billion, up 14.95% year-on-year, accounting for 52.21% of total revenue, an increase of 13.95 percentage points[15]. - Sales of health consumer products surged to RMB 658 million, a 65.21% increase year-on-year, while non-prescription drug sales reached RMB 1.714 billion, up 2.94%[15]. - Revenue from prescription drugs fell to RMB 1.583 billion, a decline of 42.94%, with sales of Danshen Chuanxiong injection dropping by RMB 1.144 billion, down 90.19%[15]. Assets and Liabilities - The company’s total assets increased by 1.07% to RMB 9.965 billion compared to the end of the previous year[11]. - The company's total assets amounted to CNY 9,965,403,645.99, an increase from CNY 9,860,341,729.66 as of December 31, 2019[40]. - Total liabilities decreased to CNY 4,532,438,024.72 from CNY 4,917,631,823.18, a reduction of approximately 7.82%[44]. - The company's equity increased to CNY 5,432,965,621.27 from CNY 4,942,709,906.48, reflecting a growth of about 9.92%[44]. - The total liabilities amounted to ¥4,917,631,823.18, with current liabilities at ¥4,295,252,579.13, and non-current liabilities at ¥622,379,244.05[73]. Cash Flow - The net cash flow from operating activities was RMB 654.20 million, a decrease of 11.85% year-on-year[11]. - Cash inflow from operating activities for the first three quarters of 2020 was 4,867,908,633.46 CNY, down from 5,825,809,730.95 CNY in 2019, representing a decrease of approximately 16.4%[64]. - Cash outflow from operating activities totaled 4,213,711,740.18 CNY in 2020, down from 5,083,700,321.61 CNY in 2019, a decrease of approximately 17.1%[64]. - Cash inflow from financing activities was 2,500,250,000.00 CNY in 2020, down from 2,888,983,000.00 CNY in 2019, a decrease of about 13.4%[64]. - The ending balance of cash and cash equivalents as of the end of the third quarter of 2020 was 1,460,676,056.80 CNY, up from 1,207,687,775.96 CNY in 2019, an increase of approximately 21%[64]. Investments and Equity - Long-term equity investments decreased by 62.59%, totaling 532,430,416.27 RMB, due to a change in accounting method for JHBP(CY) equity[27]. - The company reported an investment loss of CNY 7,818,223.62 in Q3 2020, compared to a loss of CNY 21,619,170.07 in Q3 2019[51]. - The company reported a significant increase in investment income to ¥291,387,963.96, a 627.58% increase compared to the previous year's loss of ¥55,231,161.50, primarily due to the transfer of part of the equity in JHBP (CY) and changes in accounting methods[30]. - The company completed the transfer of 533,464,040 shares (20% of total shares) to Zhejiang Provincial Traditional Chinese Medicine Health Industry Group, changing its controlling shareholder[33]. Operational Efficiency - The company is focusing on expanding its self-care product business and online retail market to mitigate the impact of policy changes and the COVID-19 pandemic[14]. - The company's employee compensation payable decreased by 31.05% to ¥66,958,143.43, primarily due to the payment of year-end bonuses during the reporting period[30]. - The company reported a 79.67% increase in prepayments, reaching 55,141,771.49 RMB, due to increased material payments[27]. - The company’s sales expenses for Q3 2020 were CNY 582,160,591.86, down 30.1% from CNY 832,688,032.59 in Q3 2019[51].